✍🏽 Landon’s Loop #185

🎙️ Chicago Futurist: John Flavin, Founder and CEO of Portal Innovations

John Flavin has been building biotech in Chicago since before most people thought Chicago had biotech.

In the 90s he helped build MediChem from 6 people to more than 230. He went on to lead UChicago's Chicago Innovation Exchange.

In March 2020 he launched Portal Innovations at Fulton Labs to give early-stage life sciences companies three things at once: capital, lab space, and people who have done it before.

Portal now runs in Chicago (Fulton Labs and the UChicago Science Incubator at Hyde Park Labs), Houston, Atlanta, Providence, and New Jersey. Its New Jersey hub opened in October with Rutgers and RWJBarnabas, and Salt Lake City is next. One of its Houston companies, CrossBridge Bio, sold to Eli Lilly in April for up to $300 million.

What gap was Portal built to fill?

JF: "To me, Portal represents the next chapter in the evolution of Chicago's ecosystem, and we were building from strength. Coming out of the 2008 credit crisis, the city had a renewed interest in entrepreneurship. That's when you saw the advent of 1871, and on its heels, a group of founders and friends put together MATTER in the Merchandise Mart.

That was the first move to coalesce the ecosystem and concentrate density around large and small companies trying to bring new products to patients. Then came INVO at Northwestern and the Polsky Center at the University of Chicago, which revolutionized how those universities get innovation out the door. Portal was built as the next generation.

We had all these new innovation sources, MATTER, mHUB, INVO, the Polsky Center, but we needed a local market.

❝

In biotech, Chicago has historically been a net exporter of talent and intellectual property to Boston and the Bay Area. That's good for patients, because those products often reach the market, but it doesn't replenish the ecosystem locally.

There are now a lot more Boston-backable faculty here. AI is heating up. Supercomputing and quantum are becoming more important. Why can't we do that here? And how do we retain the people we just recruited into these universities? So Portal was designed as a local market answer to the innovation these universities are putting out. We combine what we call crafted capital, three currencies, with early-stage venture capital and infrastructure that didn't exist in the city before.

You can't do chemistry and biology in your bathtub at home. You need the right ventilation and services. That infrastructure, plus everything that goes with building a complex biotech business from pre-seed through Series A, was the market need we saw emerging with this explosion of new talent."

Where does AI-enabled biotech fit in Chicago's story?

JF: "When I look at our differentiating strengths across the tech landscape, AI-enabled biotech has to be a theme for us. Think about the supercomputing power at Argonne and Fermilab, further catalyzed by Northwestern and the University of Chicago. We have the best of both worlds with those two institutions: Northwestern's engineering prowess coupled with the University of Chicago's deep focus on biology, immunology, and clinical applications.

One company that embodies this is Grove Biopharma, which we helped spin out of Northwestern. They're using every element of applied AI to discover what they call protein-like polymers, or bionic polymers, to deliver a new drug modality. Not a chemical, but a combination of medicinal chemistry, engineering, and AI that could be a profound step change in outcomes for patients with diseases like Parkinson's and cancer. It's still early stage, and they're working toward lead candidate designation in the next few months, but it's a great example of multidisciplinary collaboration that leverages every part of the apparatus we have here, and of how Chicago differentiates within the global biotech landscape."

Should we be marketing Chicago companies to coastal and international capital?

JF: "We focus on raising the right type of capital from the right partner, and typically only a small fraction of that is found locally. So we import capital for our deals. We benefit from a strong base of Chicago family offices as LPs, and we're very grateful for them, but that's just step one.

❝

We're building world-class companies, the kind where funds from anywhere would say, 'I want to invest in that company.

I don't care where it is. The technology, the team, and the problem they're solving are world-class.' It's a mistake to be insular or close-minded, or to have an us-versus-them mentality. If you build world-class opportunities, you can recruit money from the right partners anywhere in the world."

With federal grants shifting, where does non-dilutive capital come from now?

JF: "The federal funding environment is always shifting, and typically not increasing, but knowing where it's shifting improves an entrepreneur's chances of finding an attractive federal partner. ARPA-H is a good example of a new fund going after edgier, longer-term investments in healthcare and other areas. I'm also seeing funds shift toward defense. Portal will be working closely with an accelerator that will leverage our multi-site footprint for an Army applied platform, biotech for the warfighter, which could have civilian impact as well.

Foundations are investing more too, usually as grant-making bodies focused on one disease or area. So finding the right partners is the name of the game, whether venture, institutional, or federal, and you also have to be savvy about which state funds you can access.

Texas has a $6 billion taxpayer fund called CPRIT, the Cancer Prevention and Research Institute of Texas. Companies we've invested in there have received $15 to $20 million of non-dilutive capital each. With syndicate partners, we invested $10 million in CrossBridge Bio, and they accessed about $18 million in non-dilutive capital. About 24 months from pre-seed to exit, they sold a unique dual-payload ADC for cancer to Eli Lilly for $300 million.

The return on invested capital was enormous, thanks to that state funding. The money is out there. It's on the entrepreneur to find it, and Portal can help identify the right funding bodies."

Subscribe to my YouTube for conversations with leaders reshaping Chicago

🚆 Chicago Builds: Third Rail Recap

Last Thursday we packed the 4th floor of 600 W Chicago with the people building how Chicago moves, from robotaxis and trains to the last mile.

Chicago Builds: Third Rail was put on for an audience of 250, and it was nothing short of electric.

It was the second summit in my Chicago Builds series, after Chicago Builds: Future of Money last July, where we dug into how the city that built modern markets is building what comes next in finance.

I keep doing these because Chicago has no shortage of events, but very few put startups, investors, and policymakers in the same room. That's where things actually get built.

Lieutenant Governor-elect Christian Mitchell opened with the keynote.

Then came the question everyone showed up for: is Chicago ready for a car with no driver? Lara Dailey, Waymo’s Midwest Policy Manager, made the case in a fireside with Michael Fassnacht, Chief Growth Officer at Clayco.

Waymo also parked one of its cars on site, and for a lot of people it was the first one they had seen up close.

We also covered the O’Hare Flyer with Dave Lundy and Mark Walbrun, and NITA’s first year with Audrey Wennink of the Metro Planning Council.

Augustin Wegscheider of Ford sat down for a fireside on Ford and the future of Midwest mobility.

Kevin Green (OTR Transportation), Abdu Kholmatov (Elmeeda), and Paul Singer (Fleetworks) took on AI freight and the last mile, moderated by Krystian Gebis (ShipperCRM).

I closed with Building the City That Moves, alongside Lou Raizin, Ald. Walter Burnett (27th Ward), Lisa Clemmons Stott (Illinois DCEO), and Sean Madison (Lyft Urban Solutions).

If you want driverless cars in Chicago, Waymo set up two easy ways to say so:

💻 SC26 Week Starts with a Hack

SC26, the world’s biggest supercomputing conference, is at McCormick Place Nov 15-20, and we got a head start this weekend.

From Friday evening through Sunday afternoon, we hosted the Supercomputing Local AI Hackathon with CIQ and NVIDIA.

15 teams and 75 hackers spent about 47 hours building, with a full build day on Saturday.

The challenge was to build something real with AI that needed far more computing power than a laptop, and then show what that extra power made possible.

Each team got two powerful NVIDIA-based machines from Lenovo. Together, the 40 machines were linked into one shared supercomputer. It was almost as we had a mini data center at our office for the entire weekend.

📅 Who’s Hosting This Week in Chicago

SC26

Investing Essentials: Fireside Chat with a First-Year Venture Capitalist

25th Annual Chicago Innovation Awards

AMD + Oxide Happy Hour at SC26

Hops & Flops: Happy Hour with VAST & ByteBridge

Business Acumen Series: Q&A on AI Adoption for Small Business Operations

Beyond VC: How To Fund Your Startup

  • Thursday

  • First 3 Landon's Loop readers get in free with code LANDONSLOOP

👋 See you next week!

Follow me on Twitter and Instagram

🗞 Previous Newsletters: